| Applications: |
ELISA |
| Reactivity: |
Human |
| Note: |
FOR SCIENTIFIC EDUCATIONAL RESEARCH USE ONLY (RUO). MUST NOT BE USED IN DIAGNOSTIC OR OTHER MEDICAL APPLICATIONS. |
| Sensitivity: |
0.38ng/mL |
| Detection Limit: |
0.63~40ng/mL |
| Short Description: |
This MHCG/HLA-G Sandwich ELISA is an in-vitro enzyme-linked immunosorbent assay for the measurement of samples in human cell culture supernatant, serum and plasma (EDTA, citrate, heparin). |
| Storage Instruction: |
If unopened the kit may be stored at 2-8°C for up to 1 month. If the kit will not be used within 1 month, store the components separately, according to the component table in the manual. |
| Assay Time: |
3.5h |
| Detection: |
Colormetric |
| Gene Symbol: |
HLA-G |
| Gene ID: |
3135 |
| Uniprot ID: |
HLAG_HUMAN |
| Specificity: |
This kit recognizes Human MHCG/HLA-G in samples. No significant cross-reactivity or interference between Human MHCG/HLA-G and analogues was observed. |
| Sample Type: |
Serum, plasma and other biological fluids |
| Post Translational Modifications | N-glycosylated. Soluble HLA class I histocompatibility antigen, alpha chain G: Produced by proteolytic cleavage at the cell surface (shedding) by matrix metalloproteinase MMP2. |
| Function | Isoform 1: Non-classical major histocompatibility class Ib molecule involved in immune regulatory processes at the maternal-fetal interface. In complex with B2M/beta-2 microglobulin binds a limited repertoire of nonamer self-peptides derived from intracellular proteins including histones and ribosomal proteins. Peptide-bound HLA-G-B2M complex acts as a ligand for inhibitory/activating KIR2DL4, LILRB1 and LILRB2 receptors on uterine immune cells to promote fetal development while maintaining maternal-fetal tolerance. Upon interaction with KIR2DL4 and LILRB1 receptors on decidual NK cells, it triggers NK cell senescence-associated secretory phenotype as a molecular switch to promote vascular remodeling and fetal growth in early pregnancy. Through interaction with KIR2DL4 receptor on decidual macrophages induces pro-inflammatory cytokine production mainly associated with tissue remodeling. Through interaction with LILRB2 receptor triggers differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance. May play a role in balancing tolerance and antiviral-immunity at maternal-fetal interface by keeping in check the effector functions of NK, CD8+ T cells and B cells. Reprograms B cells toward an immune suppressive phenotype via LILRB1. May induce immune activation/suppression via intercellular membrane transfer (trogocytosis), likely enabling interaction with KIR2DL4, which resides mostly in endosomes. Through interaction with the inhibitory receptor CD160 on endothelial cells may control angiogenesis in immune privileged sites. Isoform 2: Likely does not bind B2M and presents peptides. Negatively regulates NK cell- and CD8+ T cell-mediated cytotoxicity. Isoform 3: Likely does not bind B2M and presents peptides. Negatively regulates NK cell- and CD8+ T cell-mediated cytotoxicity. Isoform 4: Likely does not bind B2M and presents peptides. Negatively regulates NK cell- and CD8+ T cell-mediated cytotoxicity. Isoform 5: Non-classical major histocompatibility class Ib molecule involved in immune regulatory processes at the maternal-fetal interface. In complex with B2M/beta-2 microglobulin binds a limited repertoire of nonamer self-peptides derived from intracellular proteins including histones and ribosomal proteins. Peptide-bound HLA-G-B2M complex acts as a ligand for inhibitory/activating KIR2DL4, LILRB1 and LILRB2 receptors on uterine immune cells to promote fetal development while maintaining maternal-fetal tolerance. Upon interaction with KIR2DL4 and LILRB1 receptors on decidual NK cells, it triggers NK cell senescence-associated secretory phenotype as a molecular switch to promote vascular remodeling and fetal growth in early pregnancy. Through interaction with KIR2DL4 receptor on decidual macrophages induces pro-inflammatory cytokine production mainly associated with tissue remodeling. Through interaction with LILRB2 receptor triggers differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance. Reprograms B cells toward an immune suppressive phenotype via LILRB1. Isoform 6: Likely does not bind B2M and presents peptides. Isoform 7: Likely does not bind B2M and presents peptides. |
| Protein Name | Hla Class I Histocompatibility Antigen - Alpha Chain GHla G AntigenMhc Class I Antigen G Cleaved Into - Soluble Hla Class I Histocompatibility Antigen - Alpha Chain GShla-G |
| Database Links | Reactome: R-HSA-1236974Reactome: R-HSA-1236977Reactome: R-HSA-198933Reactome: R-HSA-877300Reactome: R-HSA-909733Reactome: R-HSA-9705671Reactome: R-HSA-983170 |
| Cellular Localisation | Isoform 1: Cell MembraneSingle-Pass Type I Membrane ProteinEndoplasmic Reticulum MembraneEarly Endosome MembraneSoluble Hla Class I Histocompatibility AntigenAlpha Chain G: SecretedIsoform 2: Cell MembraneIsoform 3: Cell MembraneIsoform 4: Cell MembraneIsoform 5: SecretedEarly EndosomeIsoform 6: SecretedIsoform 7: SecretedCell ProjectionFilopodium MembraneHla-G Trogocytosis From Extravillous Trophoblast's Filopodia Occurs In The Majority Of Decidual Nk Cells |
| Alternative ELISA Names | Hla Class I Histocompatibility Antigen - Alpha Chain G ELISA kitHla G Antigen ELISA kitMhc Class I Antigen G Cleaved Into - Soluble Hla Class I Histocompatibility Antigen - Alpha Chain G ELISA kitShla-G ELISA kitHLA-G ELISA kitHLA-6.0 ELISA kitHLAG ELISA kit |
| Specificity | This kit recognizes Human MHCG/HLA-G in samples. No significant cross-reactivity or interference between Human MHCG/HLA-G and analogues was observed. |
| Reproducibility | Both intra-CV and inter-CV are |
Information sourced from Uniprot.org
| Item | Specifications | Storage |
| Micro ELISA Plate (Dismountable) | 96T: 8 wells ×12 strips strips | -20℃, 6 months |
| Reference Standard | 96T: 2 vials 48T: 1 vial | -20℃, 6 months |
| Concentrated Biotinylated Detection Ab (100×) | 96T: 1 vial, 120 μL 60 μL | -20℃, 6 months |
| Concentrated HRP Conjugate (100×) | 96T: 1 vial, 120 μL 60 μL | -20℃ (Protect from light), 6 months |
| Reference Standard & Sample Diluent | 1 vial, 20 mL | 2-8°C, 6 months |
| Biotinylated Detection Ab Diluent | 1 vial, 14 mL | 2-8°C, 6 months |
| HRP Conjugate Diluent | 1 vial, 14 mL | 2-8°C, 6 months |
| Concentrated Wash Buffer (25×) | 1 vial, 30 mL | 2-8°C, 6 months |
| Substrate Reagent | 1 vial, 10 mL | 2-8℃ (Protect from light) |
| Stop Solution | 1 vial, 10 mL | 2-8°C |
| Plate Sealer | 5 pieces | |
| Manual | 1 copy | |
| Certificate of Analysis | 1 copy | |
| Sample Type | Range (%) | Average Recovery (%) |
| Serum(n=8) | 89-102 | 94 |
| EDTA plasma (n=8) | 86-100 | 92 |
| Cell culture media (n=8) | 93-109 | 100 |
| | Intra-assay Precision | Intra-assay Precision | Intra-assay Precision | Inter-assay Precision | Inter-assay Precision | Inter-assay Precision |
| Sample | 1.00 | 2.00 | 3.00 | 1.00 | 2.00 | 3.00 |
| n | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 |
| Mean (ng/mL) | 1.86 | 5.71 | 15.28 | 1.85 | 5.90 | 15.91 |
| Standard deviation | 0.10 | 0.27 | 0.47 | 0.12 | 0.33 | 0.48 |
| CV (%) | 5.38 | 4.73 | 3.08 | 6.49 | 5.59 | 3.02 |
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
